

Analytical Methods for the Estimation of Relugolix – A Review

Mukthinuthalapati Mathrusri Annapurna* and Pinninti Pradeep

GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India

***Corresponding Author:** Mukthinuthalapati Mathrusri Annapurna, GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.

DOI: 10.31080/ASPS.2024.08.1128

Received: October 18, 2024

Published: October 28, 2024

© All rights are reserved by

Mukthinuthalapati Mathrusri Annapurna and Pinninti Pradeep.

Abstract

Relugolix is used to treat advanced prostate cancer in men. Relugolix is used in the treatment of advanced hormone sensitive prostate cancer and also to manage heavy menstrual bleeding and severe pain. In the present study the authors have reviewed and summarised the analytical methods so far developed for the estimation of Relugolix in pharmaceutical formulations as well as biological fluids.

Keywords: Relugolix; Pain

Introduction

Relugolix (CAS: 737789-87-6) is chemically 1-[4-[1-[[2,6-difluoro phenyl] methyl]-5-[(dimethyl amino) methyl]-3-(6-methoxy pyridazin-3-yl)-2,4-dioxothieno[2,3-d] pyrimidin-6-yl] phenyl]-3-methoxy urea with molecular weight 623.6 g/mol. Relugolix is used in the treatment of advanced hormone sensitive prostate cancer [1] and also to manage heavy menstrual bleeding and severe pain [2-4]. Relugolix is soluble in organic solvents such as Ethanol, DMSO and dimethyl formamide and the solubility in these solvents is approximately 1, 20 and 25 mg/ml respectively and the pKa value is 8.63. Relugolix is a competitive antagonist of Gonadotropin-releasing hormone receptors, thereby decreasing the release of Luteinizing hormone and ultimately Testosterone.

Relugolix is available as tablets with label claim 120 mg with brand names Rexigo (Zydus Cadila), R-Golix (Ipca Laboratories Ltd), OrgOnist (Sun Pharmaceuticals), Xelucip (Cipla Ltd) in India.




Figure 1: Chemical structure of Relugolix (C₂₉H₂₇F₂N₇O₅S).

The analytical methods such as UPLC-MS/MS [5], UPLC-MS [6], LC-MS/MS [7] RP-UPLC [8] RP-HPLC [9,10] were developed for the estimation of Relugolix and its impurities were studied by different authors in pharmaceutical dosage forms as well as biological fluids and some of the parameters were discussed in detail in Table 1.

Method	Mobile phase (v/v)	Column	Linearity (µg/mL)	Reference
UPLC-MS/MS (Rat plasma)	0.1% Formic acid: Acetonitrile	C18	0.0007-1.000	[5]
UPLC-MS (Impurities)	Acetonitrile: 0.1% ortho phosphate (50:50)	C18	1.25-7.5	[6]
LC-MS/MS (Rabbit plasma)	Acetonitrile: 0.1% Formic acid (90: 10)	Inertsil C18	0.0039-1.5	[7]
RP-UPLC (Gradient mode)(Impurities)	1 % ortho phosphoric acid: Acetonitrile	BEH RP-18	0.1-2.0	[8]
RP-HPLC	Acetonitrile: 0.1N Ammonium formate (55:45)	Zorbax	15-90	[9]
RP-HPLC (Gradient mode)LC-MS, HRMS, NMR	0.1% Formic acid: Acetonitrile	BEH C18	-	[10]

Table 1: Review of analytical methods.

Conclusion

The authors have briefly reviewed the analytical methods for the estimation of Relugolix in pharmaceutical dosage forms as well as biological fluids.

Bibliography

1. Shore ND, *et al.* "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer". *The New England Journal of Medicine* 382.23 (2020): 2187-2196.
2. Barra F, *et al.* "Relugolix for the treatment of uterine fibroids". *Drugs of Today* 55.8 (2019): 503-512.
3. Miwa K, *et al.* "Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxy-pyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor". *Journal of Medicinal Chemistry* 54.14 (2011): 4998-5012.
4. Markham A. "Relugolix: First Global Approval". *Drugs* 79.6 (2019): 675-679.
5. Liying Xing, *et al.* "An efficient UPLC-MS/MS Method established to detect Relugolix concentration in rat plasma". *Frontiers in Pharmacology* 13 (2022): 874973.
6. Thrinath SR, *et al.* "Development and validation of a method for studying Relugolix and its impurities by UPLC-MS". *Acta Chromatographica* (2024).
7. Siddhartha Lolla and Kumar Shiva Gubbiyapp. "Bio-analytical method development and validation for the quantitation of Relugolix in plasma samples by LC-MS/MS: application to bioavailability study in rabbits". *Rasayan Journal of Chemistry* 16.1 (2023): 494-501.
8. Narayanareddy P and Ramakrishna Reddy K. "A novel validated stability indicative UPLC method for Relugolix for the determination of process-related and degradation impurities". *Rasayan Journal of Chemistry* 17.2 (2024): 325-336.
9. Meruva Sathish Kumar, *et al.* "RP-HPLC method development and validation of Relugolix". *International Journal of Chemical and Biochemical Sciences* 24.6 (2023): 850-855.
10. Mohan Pulletikurthi KVK, *et al.* "Force degradation studies of Relugolix: identification, isolation and structure characterization of stress degradation products by using liquid chromatography-mass spectrometry, auto purification mass mediated preparative-high performance liquid chromatography, high resolution mass spectrometry, nuclear magnetic resonance spectroscopy". *Spectroscopy Letters* 55.2 (2022): 128-137.